Key Takeaways
- Revenue beat incoming: MetLife’s Q4 2025 PFOs surged 29% YoY to $18.7B, vastly exceeding consensus. The Q1 2026 run-rate is expected to normalize, with consensus at ~$19.5B — still healthy volume growth.
- VII in-line with guidance: Management pre-announced Q1 2026 variable investment income (VII) of $475–$525M pretax via April 7 Form 8-K, consistent with the ~$400M quarterly run-rate implied by the $1.6B FY 2026 target.
- EPS set for +12.8% YoY: Consensus forecasts Q1 2026 adjusted EPS of $2.21, up from $1.96 in Q1 2025, driven by higher VII, Group Benefits underwriting improvement, and RIS volume.
- Mexico VAT headwind front-loaded: Latin America faces a ~$50M pretax drag from Mexico VAT changes, concentrated in H1 2026. We expect this to weigh on Q1 segment earnings, though full-year guidance of 6–8% growth remains intact.
- MIM scaling rapidly: Post-PineBridge, MetLife Investment Management manages ~$742B AUM. Fee-based revenues are on track for ~30% growth in 2026; this segment is a key margin and multiple expansion driver.
- ‘New Frontier’ FCF on track: MetLife targets $25B of free cash flow over 2025–2029. Capital returns remain robust ($4.4B in FY 2025) and ROE has entered the 15–17% target band for the first time.
- Valuation compelling: At ~8.1x NTM P/E on a $9.85 consensus EPS estimate, MET trades at a discount to the large-cap life insurance peer group median (~8.4x) despite superior ROE trajectory and a cleaner business mix post-Brighthouse spin-off.
Q1 2026 CONSENSUS ESTIMATES SNAPSHOT
| Metric | Q1 2026E | Prior Period | Change |
|---|---|---|---|
| Adjusted EPS | $2.21E | $1.96 (Q1 2025) | +12.8% YoY |
| Premiums, Fees & Other | ~$19.5BE | $13.5B (Q1 2025) | +44.4% YoY |
| Variable Inv. Income | $500ME (midpoint) | $1.6B FY guidance | In-line |
| Group Benefits Adj. Earn. | ~$450ME | $420M (Q1 2025) | +7.1% YoY |
| RIS Adj. Earnings | ~$420ME | $360M (Q1 2025) | +16.7% YoY |
| Net Investment Income | +16.3%E YoY | — | Consensus |
Published: May 5, 2026 | Analyst: Equity Research | For institutional use only SECTION 1: Q4 2025 RESULTS ANALYSIS & Q1 2026 SETUP
Fourth Quarter 2025 — Record Earnings Quarter
MetLife delivered a record earnings quarter in Q4 2025, with adjusted EPS (excluding notable items) of $2.58, up 24% year-over-year from $2.08 in Q4 2024 and meaningfully above the consensus estimate of approximately $2.32. Premiums, fees and other revenues (PFOs) of $18.7 billion grew 29% year-over-year, also surpassing estimates, aided by substantial pension risk transfer (PRT) volume and the first full quarter of PineBridge Investments contribution to MetLife Investment Management. Full-year 2025 adjusted EPS of $8.89 (up 10% year-over-year) came in at the upper end of management’s implied guidance range, reflecting outperformance across Group Benefits underwriting, record RIS transaction volumes, and higher-than-expected variable investment income in Q4. The company returned $4.4 billion to shareholders in FY 2025 ($2.9B buybacks + $1.5B dividends) while maintaining holding company cash of $3.6 billion — within the $3.0–$4.0B target corridor. Exhibit 1: Q4 2025 Beat vs. Consensus Estimates | Source: Company filings, Bloomberg consensus (Feb 4, 2026) Exhibit 2: Quarterly Adjusted EPS Trend (Q1 2024 – Q1 2026E) | Source: MetLife Q4 2025 Earnings Release (Feb 4, 2026); Bloomberg consensus Segment Performance Deep-Dive (Q4 2025) Group Benefits — $465M adjusted earnings (+12% YoY) Continued underwriting improvement with strong dental/vision performance and mortality in-line with expectations. New PFOs of $600M added in FY 2025, with higher-margin voluntary PFOs growing 10% YoY. We expect Q1 2026 to show seasonally higher group life mortality but broadly maintain the mid-single-digit growth trajectory. Retirement & Income Solutions (RIS) — $454M adjusted earnings (+18% YoY) Record FY 2025 PRT transaction volume of $14.2B and U.K. longevity reinsurance of $11.1B. RIS faces a $300–$325M annual earnings headwind from interest rate caps rolling off and base spread compression (~$0.20/share). Q1 2026 RIS earnings are likely to step down from Q4’s elevated level; our estimate is ~$420M. Latin America — $210M adjusted earnings (est. Q4) Constant-currency sales grew 12% in FY 2025, led by Mexico. However, the segment faces a ~$50M pretax headwind from Mexico VAT changes concentrated in H1 2026. The full-year 2026 guidance for 6–8% growth remains attainable if the VAT impact is non-recurring, but Q1 will reflect the majority of that drag. MetLife Investment Management (MIM) — $55M adjusted earnings (Q4 2025; first full quarter post-PineBridge) MIM closed the PineBridge acquisition in mid-2025 and ended Q4 2025 with $742B AUM versus ~$600B at year-end 2024. Management guides for ~30% revenue growth and $240–$280M adjusted earnings in FY 2026 — a step-change for this segment. Q1 2026 AUM is estimated at ~$780B as private credit fundraising accelerates. Exhibit 3: Q4 2025 Adjusted Earnings by Segment | Source: MetLife Q4 2025 Earnings Call (Feb 5, 2026) SECTION 2: KEY METRICS & GUIDANCE UPDATE
Variable Investment Income — Critical Pre-Announcement
On April 7, 2026, MetLife filed an 8-K disclosing preliminary Q1 2026 variable investment income (VII) of $475–$525 million pretax — ahead of the full earnings release on May 6. This compares favorably to the ~$400M quarterly average implied by the company’s full-year 2026 guidance of approximately $1.6 billion, though the $500M midpoint is sequentially below Q4 2025’s estimated $480M. The Q1 2026 VII pre-announcement is meaningful because: (1) VII is a significant driver of MetLife’s adjusted earnings volatility, contributing to approximately 15–20% of total adjusted earnings; (2) private equity and real estate returns began 2026 positively after a challenging interest rate environment in late 2025; and (3) prepayment fees — another component of VII — benefited from refinancing activity as spreads tightened. Exhibit 4: Variable Investment Income Trend ($M, Pretax) | Source: MetLife 8-K filings; Q4 2025 Earnings Release (Feb 4, 2026) Exhibit 5: Quarterly Premiums, Fees & Other Revenues ($B) | Source: MetLife Quarterly Earnings Releases, 2024-2026
Full-Year 2026 Segment Guidance
| Segment / Metric | FY 2026 Guidance | YoY Growth | Key Drivers |
|---|---|---|---|
| Group Benefits | $1.87–$1.92B | +7–9% YoY | PFO growth 4–7%; strong voluntary benefits |
| Retirement & Income | $1.60–$1.80B | Flat-+9% YoY | Rate cap headwind ($300–325M) partially offset by volume |
| Latin America | $0.87–$0.89B | +6–8% YoY | Mexico VAT drag ~$50M in H1 2026 |
| MetLife Inv. Mgmt | $0.240–$0.280B | NM (new segment) | 30% revenue growth; PineBridge synergies |
| Variable Inv. Income | ~$1.6B | FY guidance | ~$400M quarterly average |
| Free Cash Flow | ~$5.0B | Part of $25B target | 65–75% FCF/earnings ratio |
Exhibit 6: Segment Adjusted Earnings — FY 2025 Actual vs. FY 2026 Guidance | Source: MetLife Q4 2025 Earnings Release & Outlook Conference (Feb 2026) SECTION 3: INVESTMENT THESIS UPDATE Thesis: Intact with Incremental Positive Catalysts Our BUY thesis on MetLife is centered on three pillars: (1) the secular growth of employer-sponsored benefits and institutional annuities driving durable top-line expansion; (2) the emergence of MetLife Investment Management as a scaled, fee-generating asset manager creating an underappreciated earnings stream; and (3) disciplined capital return and balance sheet management supporting 15–17% adjusted ROE. All three pillars remain structurally intact after Q4 2025. The Q1 2026 setup is modestly favorable given the 8-K pre-announcement of VII in the upper half of management’s quarterly implied range. The primary near-term headwind — the RIS interest rate cap roll-off — is well-disclosed and partially priced in.
What’s Changed vs. Prior View
- Positive: PineBridge AUM ramp is tracking ahead of plan. MIM reached $742B AUM at year-end 2025 versus a $700B internal target, and is on track for $800B+ by mid-2026. Fee revenues are expected to grow ~30% in FY 2026, which we view as conservative given current fundraising momentum in private credit.
- Positive: Group Benefits underwriting improvement has been more durable than expected. FY 2025 was the second consecutive year of above-target underwriting margins, driven by favorable mortality trends and product repricing initiatives.
- Incremental risk: The Mexico VAT change introduces a $50M H1 2026 headwind to Latin America that was not fully reflected in sell-side models at the time of the Q4 earnings release. We have incorporated this in our Q1 2026 segment estimates.
- Neutral: RIS rate cap headwind of $300–$325M annually was pre-disclosed at the February 2026 Outlook Conference. The spread compression impact (~$0.20/share) is manageable given the volume growth tailwind from PRT demand. Exhibit 7: Adjusted ROE vs. 15-17% Target Range | Source: MetLife Annual Reports; FY 2026E based on Bloomberg consensus Exhibit 8: Capital Return to Shareholders ($B) | Source: MetLife Q4 2025 Earnings Release (Feb 4, 2026)
Risk/Reward Assessment
Key Risks
- Interest rate sensitivity: The RIS segment faces a $300–325M annual earnings headwind from rate cap roll-off. Further spread compression if the yield curve flattens could incrementally pressure this segment.
- Private equity return variability: VII (approximately 15-20% of adjusted earnings) is tied to PE/real estate fund returns. A market downturn would reduce VII and compress earnings.
- Latin America political risk: Mexico VAT changes and FX volatility could create recurring headwinds beyond H1 2026 if policy uncertainty escalates.
- Credit quality: As a major corporate bond investor, MET is exposed to credit spread widening, particularly in investment-grade industrials where it holds concentrated positions.
Key Catalysts
- Q1 2026 earnings (May 6, 2026): Results due tomorrow. VII pre-announced at $475–$525M supports EPS approaching $2.21 consensus. An upside surprise in Group Benefits or RIS volumes could drive shares higher.
- MIM AUM milestones: Crossing $800B AUM in mid-2026 could re-rate the stock as investors apply a higher multiple to the fee-based asset management earnings stream.
- Capital deployment: Management authorized $3.0B+ of buybacks for 2026. Continued aggressive repurchase at current depressed valuations (~8x P/E) is highly accretive.
- Dividend increase: MetLife has consistently grown its dividend. A mid-year increase (historically announced in Q2) would be a positive signal. SECTION 4: VALUATION & UPDATED ESTIMATES
Valuation Framework
We value MetLife using a blended approach: (1) NTM P/E multiple on consensus EPS, benchmarked to the life insurance peer group; and (2) an adjusted book value (ABV) multiple, reflecting the company’s growing asset-light income streams. At the current price of $80.15, MET trades at approximately 8.1x the NTM consensus EPS of $9.85. This represents a modest discount to the peer group median of ~8.4x. Our price target of $96 is derived from applying a 9.75x multiple to our FY 2026 adjusted EPS estimate of $9.85, which we view as achievable given the ROE trajectory entering the target 15–17% range and the growing MIM contribution. Exhibit 9: NTM P/E vs. Life Insurance Peer Group | Source: Bloomberg consensus as of May 5, 2026 Exhibit 10: MetLife Investment Management AUM Growth ($B) | Source: MetLife Quarterly Reports 2023–2026E
Updated Estimates Summary
| Metric | FY 2026E | FY 2025 Actual | Notes |
|---|---|---|---|
| Q1 2026E Adj. EPS | $2.21 | $9.85 | Bloomberg consensus as of May 5, 2026 |
| FY 2026E Adj. EPS | $9.85 | $8.89 | +10.8% YoY; consensus |
| FY 2026E PFOs | ~$57.6B | $57.6B | Flat-ish YoY on PRT normalization |
| FY 2026E ROE | ~16% | ~15.6% | Within 15-17% target band |
| FY 2026E Variable II | ~$1.6B | ~$1.7B | Slightly below FY25 on normalization |
| FY 2026E FCF | ~$5.0B | ~$4.4B | 65-75% FCF/adj. earnings ratio |
Exhibit 11: New Frontier $25B Free Cash Flow Target (2025-2029) | Source: MetLife Investor Day / Outlook Conference (Feb 2026) Exhibit 12: Analyst EPS Estimate Revisions — FY 2026 & Q1 2026 | Source: Bloomberg consensus, December 2025 – April 2026
Scenario Analysis
| Scenario | Q1 2026E EPS | FY 2026E EPS | Price Target | Key Assumptions |
|---|---|---|---|---|
| Bull Case | ~$2.45+ | >$10.20 | ~$110 | VII above $525M; Group Benefits margin >4.5%; Mexico VAT one-time |
| Base Case | ~$2.21 | ~$9.85 | ~$96 | VII at $500M; Consensus EPS; ROE enters 15-17% band |
| Bear Case | ~$1.90 | ~$8.80 | ~$75 | VII misses; RIS spread compression worsens; LatAm ongoing drag |
SOURCES & REFERENCES
All figures cited herein are sourced from primary company disclosures, SEC filings, and third-party consensus data. Hyperlinks below are clickable (Ctrl+Click to open). Earnings Materials:
- MetLife Q4 2025 & Full Year 2025 Earnings Press Release (February 4, 2026)
- MetLife Q4 2025 Earnings Call Transcript (February 5, 2026)
- MetLife Form 8-K — Q1 2026 Variable Investment Income Pre-Announcement (April 7, 2026)
- MetLife Form 8-K — 2026 Outlook Conference (February 2026)
MetLife Investor Relations — Quarterly Results
MetLife Investor Relations — News & Presentations
- MetLife Form 10-K (FY 2025) — SEC EDGAR
- Bloomberg Consensus Estimates as of May 5, 2026 — via FactSet/Bloomberg
- Barchart — What to Expect From MetLife Q1 2026 Earnings (April 9, 2026)
- Zacks — Can Higher Investment Income Help MetLife Deliver Q1 Beat (May 2026)
- Seeking Alpha — MetLife $25B FCF Target (New Frontier)
MarketBeat — MET Analyst Ratings and Price Targets
IMPORTANT DISCLAIMER
This report is a pre-earnings preview prepared as of May 5, 2026, the day before MetLife’s scheduled Q1 2026 earnings release. All Q1 2026 estimates are based on consensus analyst forecasts, management pre-announcements (Form 8-K filed April 7, 2026), and publicly available information. Actual results may differ materially from estimates. This report does not constitute investment advice. All data sourced from public disclosures, Bloomberg, and FactSet. Past performance is not indicative of future results. Analysts and their affiliated institutions may hold positions in securities mentioned herein. Price targets represent 12-month views.